tirzepatide cardiovascular outcomes trial In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT Tirzepatide Matches Dulaglutide in Large
Pay in 4 interest-free payments of $7.02 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3

























